A zoonotic virus belonging to the Orthopoxvirus genus, monkeypox has resurfaced as a global health concern outside of its endemic areas in central and western Africa. Symptoms of the virus appear 6–13 days after contact and include fever, rash, lymphadenopathy, and serious consequences in immunocompromised patients. The Central African clade, one of the two primary clades, has a greater mortality rate than the West African one. Since the first human case occurred in 1970, outbreaks have been documented on several continents, especially after smallpox vaccination campaigns were discontinued. Recent worldwide outbreaks, which have included thousands of cases documented in Europe, Africa, and the Americas, highlight the significance of effective antiviral therapies, immunisation programs, and surveillance. Since 2022, a number of cases have been confirmed in India, and efforts are still being made to enhance public health response and readiness. In order to shed light on the changing nature of monkeypox and methods for lessening its effects, this short communication explores the epidemiology, clinical presentation, immunisation, and treatment techniques. Controlling future epidemics and halting broad transmission requires improved research, more public awareness, and targeted immunisation for high-risk groups.